Previous studies with cholinesterase inhibitors in patients with Alzheimer's Disease (AD), and the ongoing multi-center study of THA, suggests that a subgroup of patients with (AD) are responsive to this pharmacological intervention. However, a substantial proportion of patients are virtually unaffected by the administration of cholinesterase inhibitors. Data generated in animals with combined lesions of the nucleus basalis and locus coeruleus indicate that the addition of a locus coeruleus lesion to animals with nucleus basalis lesion completely eliminated responsivity to cholinomimetic agents. However the administration of the alpha II agonist clonidine, combined with a cholinomimetic, restores the ability of the cholinomimetic compound to reverse the poor performance associated with a nucleus basalis lesion. These data suggest that it is essential to the efficacy of a cholinergic compound that there be an intact central noradrenergic system. In addition these data constitute the foundation of a hypothesis proposing that some of the nonresponsivity to cholinomimetic agents, and the variable therapeutic effects observed following the administration of these compounds, may be a manifestation of variable noradrenergic degeneration in the AD brain. Specifically, those Alzheimer;s patients with a profound noradrenergic deficit would be anticipated to have no alleviation of symptoms following the administration of a cholinesterase inhibitor. In order to test this hypothesis a series of antemortem noradrenergic markers will be investigated for the possibility that they will be predictive of responsivity to the cholinesterase inhibitor THA alone combined with either clonidine, deprenyl, or desipramine. In a second parallel investigation the validity of these antemortem noradrenergic markers will be tested in a separate cohort of new stage Alzheimer;s patients whose antemortem parameters will be composed with the changes on post mortem examination in noradrenergic parameters when these same Alzheimer;s patients are autopsied.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-07
Application #
3809200
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Silverman, Jeremy M; Schmeidler, James (2018) Outcome age-based prediction of successful cognitive aging by total cholesterol. Alzheimers Dement 14:952-960
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10
Warren, Noel A; Voloudakis, Georgios; Yoon, Yonejung et al. (2018) The product of the ?-secretase processing of ephrinB2 regulates VE-cadherin complexes and angiogenesis. Cell Mol Life Sci 75:2813-2826

Showing the most recent 10 out of 555 publications